InsidersTradesSigma
Follow the 현대바이오 share price and the full management transaction log of the company, a publicly traded company based in South Korea. Shares trade on the KR market, under the supervision of DART (FSS). Operating in the Health Care sector, 현대바이오 has logged 8 public disclosures. Market capitalisation: €620.5bn. The latest transaction was reported on 30 June 2026 (Purchase). Among the most active insiders: 씨앤팜. All data is openly available.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Hyundai Bio is a company operating in the health and pharmaceutical sector, listed on the XKRX market. It focuses on developing innovative biopharmaceutical solutions.